Personalised Immunotherapy in Sepsis:
a precision medicine approach

Immune classification in sepsis

Results of the PROVIDE study, sponsored by ImmunoSep partner and clinical trial coordinator, Hellenic Institute for the Study of Sepsis, on 240 patients with septic shock achieved the immune classification into macrophage activation-like syndrome, sepsis-induced immunoparalysis, and intermediate state. These entities have different pathogenesis and outcomes. Results are published at Cell Reports Medicine and can be found here.